Focus: Baxter International is a $10.4B global medical device and specialty pharma company with 50,000+ employees, commanding a diversified portfolio in renal care, critical care, and nutritional therapies. The company is heavily concentrated on TRUDHESA (dihydroergotamine mesylate) for migraine, which represents 100% of revenue concentration.
Profile data last refreshed 14h ago · AI intelligence enriched 3d ago
Hot — 636 jobs added in 30d
Net +123 (636 new, 513 removed). Aggressive expansion phase.
Baxter offers stability and scale for operational/IT-focused careers, but extreme product concentration and low R&D spend make it a risky bet for scientists seeking innovation-driven roles or long-term R&D career growth.
Help build intelligence for Baxter International
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Baxter International's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Post-LOE generic with minimal Part D uptake ($5K); represents legacy portfolio management with low commercial relevance.
Commodity electrolyte product with minimal Part D spending; core portfolio staple with patent protection through 2039 but negligible revenue contribution.
Post-LOE generic muscle relaxant with no reported Part D spending; mature commodity product.
Critical care agent approaching loss of exclusivity; specialty indication but no reported Part D revenue signal.
IV solution formulation approaching LOE; core critical care infrastructure product with stable but low-margin revenue.
IV solution formulation approaching LOE; commodity fluid product with stable demand in hospital settings.
Post-LOE antiprotozoal for rare opportunistic infection; niche indication with minimal revenue impact in modern era.
Pre-launch formulation for joint care; early-stage product with undefined commercial trajectory.
Post-LOE amino acid formulation for nutritional support; core hospital/ICU infrastructure product with steady institutional demand.
181 discontinued, 128 duplicate formulations not shown
+87 more products
The Best Healthcare Stocks to Buy - Morningstar
The Best Healthcare Stocks to Buy Morningstar
Mankind Pharma Appoints Anish Bafna as Independent Director - https://hrtoday.in/
Mankind Pharma Appoints Anish Bafna as Independent Director https://hrtoday.in/
8-K Filing: Zoetis Inc. (ZTS) (CIK 0001555280) — EX-99.1
EX-99.1
8-K Filing: CARDINAL HEALTH INC (CAH) (CIK 0000721371) — 8-K
8-K
8-K Filing: Obsidian Therapeutics, Inc. (OBX) (CIK 0002130606) — 8-K
8-K
Baxter issues recall of antibiotic IV bags after bits of cardboard flagged in solution - Fierce Pharma
Baxter issues recall of antibiotic IV bags after bits of cardboard flagged in solution Fierce Pharma
Showing 6 of 10 news items
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Recent peer-reviewed publications with author affiliations at this company
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo